Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

Stock Performance - Vertex Pharmaceuticals closed at $440 68, down 0 72% from the previous session, underperforming the S&P 500's gain of 0 92%, the Dow's gain of 0 31%, and the Nasdaq's gain of 2 03% [1] - Over the past month, the company's shares gained 11 15%, outperforming the Medical sector's gain of 3 83% and the S&P 500's gain of 0 81% [1] Earnings and Revenue - The company's upcoming earnings report is expected on February 10, 2025, with projected EPS of$ 4, reflecting a 4 76% decrease from the same quarter last year [2] - Revenue is expected to be $2 78 billion, up 10 29% from the prior-year quarter [2] Analyst Forecasts and Revisions - Recent revisions to analyst forecasts for Vertex Pharmaceuticals are important as they reflect changing near-term business trends [3] - Positive estimate revisions are generally a good sign for the company's business outlook [3] - The Zacks Consensus EPS estimate has shifted 0 34% downward over the past month [5] Valuation Metrics - Vertex Pharmaceuticals is trading at a Forward P/E ratio of 24 39, which is a premium compared to the industry average of 22 85 [6] - The company has a PEG ratio of 2, higher than the industry average of 1 39 for Medical - Biomedical and Genetics stocks [6] Industry Ranking - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [7] - Top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]